Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMC Surg ; 21(1): 133, 2021 Mar 16.
Article in English | MEDLINE | ID: mdl-33726732

ABSTRACT

BACKGROUND: Gall bladder cancer (GBC) is the fifth most common malignancy in the gastrointestinal system and the most common malignancy of the biliary system. GBC is a very aggressive malignancy having a 5 year survival rate of 19%. Giant Gall Bladder (GGB) is an uncommon condition that can result from cholelithiasis or chronic cholecystitis and rarely with malignancy. CASE REPORT: A 65 year old lady presented with vague abdominal pain for 12 years and right abdominal lump of size 20 × 8 cms was found on examination. CT scan showed a circumferentially irregularly thickened wall (2.5 cm) of gall bladder indicative of malignancy. Per-operatively a GB of size 24 × 9 cm was noted and patient underwent radical cholecystectomy. It was surprise to find such a giant malignant GB with preserved planes. Histopathology, it was well differentiated adenocarcinoma of gall bladder of Stage II (T2a N0 M0). DISCUSSION: It is known that mucocoele of GB can attain large size, however chronic cholecystitis will lead to a shrunken gall bladder rather than an enlarged one. A malignant GB of such size and resectable is rare without any lymph node involvement or liver infiltration. Few cases of giant benign gall bladder have been reported in literature, however this appears to be the largest resectable gall bladder carcinoma reported till date as per indexed literature. CONCLUSION: Giant GB is an uncommon finding. They are mostly benign, however malignant cases can occur. Radiological findings may suggest features of malignancy and define extent of disease. Prognosis depends on stage of disease and resectability, irrespective of size.


Subject(s)
Carcinoma , Gallbladder Neoplasms , Aged , Carcinoma/diagnostic imaging , Carcinoma/surgery , Cholecystectomy , Female , Gallbladder Neoplasms/diagnostic imaging , Gallbladder Neoplasms/surgery , Humans , Tomography, X-Ray Computed
2.
J Med Cases ; 11(6): 174-177, 2020 Jun.
Article in English | MEDLINE | ID: mdl-33984088

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ravaged the global society as we know it. As almost a dozen pharmaceutical agents go into randomized controlled clinical trials, multiple studies have surfaced trying to associate a hypercoagulable state to coronavirus disease 2019 (COVID-19) patients. We report two COVID-19 cases who presented with occlusive pulmonary embolism (PE) strongly supporting a hypercoagulable state incurred by SARS-CoV-2. This is significant as it is one of the early reports of such an initial presentation of COVID-19 in the USA. Through our report, we invite the medical community to share a perspective about long-term management guidelines for SARS-CoV-2 associated venous thromboembolism (VTE) and prompt future research.

3.
BMC Cancer ; 19(1): 449, 2019 May 14.
Article in English | MEDLINE | ID: mdl-31088420

ABSTRACT

BACKGROUND: Treatment of solid malignancies has been revolutionized with the introduction of immune checkpoint inhibitors (ICIs) and their use is being expanded in therapy of different cancers. However, immune related adverse events (IRAEs) can occur during treatment. These side effects occur due to stimulation of the innate and adaptive immune system and can lead to serious complications. Recently, acral ischemia has been reported in some cases during treatment with programmed death-1 (PD-1) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitors. Here, we discuss a case in which acral necrosis developed after initiation of a PD-1 inhibitor. We offer a review of the existing literature on the pathophysiology, clinical course and treatment outcomes. CASE PRESENTATION: A 68-year-old female was diagnosed with stage IV non-small cell lung adenocarcinoma and was started on pembrolizumab. The patient developed sudden onset numbness and discoloration of fingertips bilaterally at week 25 after initiation of ICI treatment. Extensive workup to rule out hypercoagulable, autoimmune and vascular disease was unremarkable except for mild elevation of ANA and ESR. The symptoms quickly progressed into dry gangrene within four weeks and did not respond to medical or surgical treatment. Pembrolizumab was subsequently discontinued due to progression of metastatic disease. The patient refused further interventions and transitioned to hospice care where she expired after two months. CONCLUSION: Acral ischemia can develop during treatment of malignancies. This complication, although uncommon, canresult in digital amputation. Physicians should be aware of the possible progression of acral vascular necrosis when Raynaud's like symptoms develop. Larger studies are needed to confirm the role of ICIs in the pathogenesis of acral vascular necrosis.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Fingers/pathology , Aged , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Agents, Immunological/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Disease Progression , Fatal Outcome , Female , Fingers/surgery , Gangrene , Humans , Lung Neoplasms/drug therapy
4.
Clin Pract ; 1(4): e106, 2011 Sep 28.
Article in English | MEDLINE | ID: mdl-24765347

ABSTRACT

Pemetrexed is an antifolate chemotherapy agent that is active in malignant mesothelioma and non-small cell lung cancer (NSCLC). Pneumonitis is a rare side effect of Pemetrexed. We report the case of 72-year-old female with metastatic poorly differentiated lung adenocarcinoma. She was placed on maintenance pemetrexed and developed gradual progressive dyspnea after first cycle of maintenance of pemextrexed. The computed tomography (CT) of the chest showed ground glass opacity in both lung fields. Transbronchial lung biopsy showed uniform interstitial widening by a cellular chronic infiltrate with areas of type II pneumocyte and exudation of pale eosinophilic edema fluid; features consistent with acute lung injury. Patient improved both clinically and radiological after stopping pemetrexed and starting prednisone. Although pemetrexed induced lung injury is relatively rare, with the increasing use of peme-trexed in first-line treatment and in maintenance therapy of non-small cell lung cancer, awareness of this potential adverse effects is important.

5.
Int J Clin Oncol ; 15(6): 642-4, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20602134

ABSTRACT

A 60-year-old Caucasian female presented with stage IIA (T2N0M0) estrogen- and progesterone-negative and HER2-positive breast cancer. She was started on an adjuvant chemotherapy regimen of docetaxel, carboplatin, and trastuzumab (TCH). She tolerated the first two cycles of the TCH regimen well. However, 3-4 days after the third and fourth cycles, she developed acute pancreatitis. Elevated pancreatic enzymes and abdominal computed tomography (CT) imaging findings confirmed the diagnosis of acute pancreatitis. Common causes of pancreatitis were ruled out. Given the time course it was assumed that the chemotherapy was the cause of pancreatitis in our patient. The patient did not receive any further docetaxel and carboplatin chemotherapy but continued on adjuvant trastuzumab alone for a planned duration of 1 year without any recurrence of acute pancreatitis.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Pancreatitis/chemically induced , Acute Disease , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carboplatin/administration & dosage , Carmustine/administration & dosage , Chemotherapy, Adjuvant , Docetaxel , Female , Humans , Middle Aged , Neoplasm Staging , Pancreatitis/metabolism , Pancreatitis/pathology , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Taxoids/administration & dosage , Tomography, X-Ray Computed
6.
Leuk Lymphoma ; 50(9): 1434-41, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19603344

ABSTRACT

Low CD34 + cell doses increase allograft-related mortality and very high doses increase the risk of graft-versus-host disease. The optimum CD34 + cell dose remains undefined. The effect of the CD34 + cell dose based on ideal weight was analyzed in 130 patients with hematologic malignancies undergoing reduced-intensity allogeneic blood cell transplantation in the context of factors known to affect the outcome: chemosensitivity, donor age, lactate dehydrogenase (LDH), human leukocyte antigen (HLA) match, performance status, and platelet count. The survival of patients receiving >8 x 10(6)/kg CD34 + cells was not significantly different from those receiving <6. The outcome of those receiving 6-8 x 10(6)/kg CD34 + cells was significantly better than the rest. This superiority was confirmed in multivariable analysis. Among patients receiving 8) needs further confirmation.


Subject(s)
Antigens, CD34/metabolism , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/standards , Hematopoietic Stem Cells/cytology , Adult , Aged , Calibration , Cell Count , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cells/metabolism , Humans , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning/methods , Transplantation, Homologous , Young Adult
7.
Blood ; 114(1): 38-9, 2009 Jul 02.
Article in English | MEDLINE | ID: mdl-19411633

ABSTRACT

"Stringent" complete remission in myeloma has been defined by a normal serum free light chain ratio (SFLCR) in addition to the standard criteria for CR. 2648 serial samples from 122 IgG or IgA myeloma patients were studied to explore the relationship between SFLCR and serum immunofixation electrophoresis (SIFE). SFLCR was normal in 34% of cases with positive SIFE and abnormal in 66%. SFLCR was normal in 69% of cases with negative SIFE and abnormal in 31%. When evaluated with SIFE as the benchmark, the sensitivity of SFLCR was 66% and specificity was 69%. These findings were unchanged when abnormal SFLCR values were classified as concordant (< 0.26 for lambda disease and > 1.65 for kappa) or discordant (< 0.26 for kappa disease and > 1.65 for lambda). Additional studies are required to determine the temporal relationship between SFLCR normalization and paraprotein clearance. Until then, the role of SFLCR in defining response remains controversial.


Subject(s)
Immunoglobulin Light Chains/blood , Multiple Myeloma/blood , Multiple Myeloma/immunology , Myeloma Proteins/analysis , Blood Protein Electrophoresis/methods , Blood Protein Electrophoresis/statistics & numerical data , Humans , Immunoelectrophoresis/methods , Immunoelectrophoresis/statistics & numerical data , Remission Induction , Retrospective Studies , Sensitivity and Specificity , Tumor Burden
8.
J Neurooncol ; 83(1): 81-3, 2007 May.
Article in English | MEDLINE | ID: mdl-17205388

ABSTRACT

We report a case in which the only presenting symptoms of the underlying ovarian malignancy were that of paraneoplastic cerebellar degeneration and nonbacterial thrombotic endocarditis. If suspecting paraneoplastic cerebellar degeneration and nonbacterial thrombotic endocarditis, complete physical examination, including pelvic exams in female patients is warranted. Investigations should include CT chest/abdominal/pelvis, MRI brain, and Transesophageal Echocardiogram. Early recognition will lead to early diagnosis of occult malignancy and initiation of appropriate therapy. Awareness of these complications as initial presentation for internists, gynecologists and neurologists may avoid diagnostic delay.


Subject(s)
Endocarditis/etiology , Ovarian Neoplasms/complications , Paraneoplastic Cerebellar Degeneration/etiology , Pulmonary Embolism/etiology , Thrombosis/etiology , Adenocarcinoma/complications , Adenocarcinoma/diagnostic imaging , Echocardiography, Transesophageal , Endocarditis/diagnostic imaging , Fatal Outcome , Female , Humans , Middle Aged , Mitral Valve/diagnostic imaging , Ovarian Neoplasms/diagnostic imaging , Pulmonary Embolism/diagnostic imaging , Thrombosis/diagnostic imaging , Tomography, X-Ray Computed
9.
Int J Cardiovasc Imaging ; 23(5): 591-3, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17171430

ABSTRACT

Transient left ventricular apical hypokinesis results in a typical ampullary shape and has been described as Takotsubo cardiomyopathy (TCM). We report a case of TCM with the rare complication of left ventricular thrombus formation. Cardiac magnetic resonance imaging aided the diagnosis by characterizing the non-enhancing mass and evaluating the surrounding myocardium for scarring.


Subject(s)
Heart Diseases/pathology , Magnetic Resonance Imaging , Takotsubo Cardiomyopathy/complications , Thrombosis/pathology , Aged , Echocardiography , Heart Diseases/etiology , Heart Diseases/physiopathology , Heart Ventricles/pathology , Humans , Male , Radionuclide Ventriculography , Takotsubo Cardiomyopathy/pathology , Takotsubo Cardiomyopathy/physiopathology , Thrombosis/etiology , Thrombosis/physiopathology , Ventricular Function, Left
SELECTION OF CITATIONS
SEARCH DETAIL
...